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Virtually all kidney tumours of children were Wilms’ and there was
a striking preponderance in girls. 70% of eye tumours were
retinoblastoma. The relative frequency ofretinoblastoma was much
higher than it is in western countries.
Data from the population-based registries at Bangalore, Bombay,
and Madras indicate paediatric cancer frequencies varying from
37% to 4% 23 In Dibrugarh in north-eastern India and
Chandigarh in the north-west the frequency was 2-48%.
International comparisons of cancer incidence are potentially
fraught by variability in diagnosis, classification, and coding
practices, by competing causes of death, by differential access to
medical care, and by incomplete registration, so patterns need
cautious interpretation. Leukaemia is the leading type of cancer and
malignant tumours of the CNS are the second most common cancer
in childhood in several countries.2,-u, Lymphomas are the
commonest cancer (59%) among Nigerian children, with Burkitt’s
lymphoma accounting for 87% of all lymphatic malignancies.’ A
low incidence of Wilms’ tumour has been reported from China.8
Variations in the population distribution of these cancers suggest
differences in aetiology. Parental recall of exposure histories has a
major role in retrospective studies of risk factors in children, and
several factors (genetic factors, birth characteristics, environmental,
infectious) have been identified. The establishment of committed
paediatric cancer registries in India would contribute usefully to
clinical and epidemiological research.
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LeVeen shunt with wandering tip
SiR,&mdash;The LeVeen peritoneovenous shunt has been used for
nearly 20 years in the treatment of intractable ascites due to chronic
liver disease. However, the technique has a high failure rate due to
shunt occlusion.1 An uncontrolled study has suggested that the
incidence of shunt occlusion due to thrombosis may be reduced if a
titanium tip is used (fig 1).2 This tip is not part of the standard
catheter assembly but is attached to the venous end at the time of
insertion using silicone adhesive. We report here a complication
resulting from our first experience of this modification.
The patient was a 52-year-old man with alcoholic cirrhosis
diagnosed 1 year previously. Despite total abstinence he had tense
ascites, unresponsive to fluid restriction and diuretics. Twice-
weekly paracentesis meant that the patient was unable to resume
normal activities and he was reluctant to leave hospital. A LeVeen
shunt was inserted, draining to the left internal jugular vein.
Function seemed satisfactory at first but ascites reaccumulated
within a few days. Contrast studies confirmed shunt patency but
scintigraphy, 3 weeks after insertion of the shunt, indicated very
slow clearance of radiolabelled albumin from the abdomen. A week
later the shunt was removed without difficulty and a new shunt with
a titanium tip was positioned in the right internal jugular vein.
Despite reverse Valsalva exercises and a surgical corset, the ascites
once again reaccumulated.
Liver transplantation was felt to be the sole remaining option, and
the second shunt was removed after 1 month. The rectus incision
Fig 1- titanium tip to LeVeen shunt.
Length 3 cm.
Fig 2-X-ray views of detached tip.
was reopened and the abdominal portion of the shunt was retrieved.
The venous limb was delivered by gentle traction, although more
resistance was evident than with the previous untipped shunt. The
titanium tip was missing. Palpation of the right supraclavicular fossa
revealed a firm mass. After X-ray screening (fig 2) the site was
explored and the tip was found to be incarcerated at the jugular
venotomy site by a ring of fibrous tissue. It was recovered without
further mishap.
This case highlights the potential dangers of "self-assembly" of
biocompatible implants, especially those positioned intravascularly.
Detachment and embolism seem a real risk. If the titanium tip is to
be widely adopted it might be wise to have it bonded to the
peritoneovenous shunt at the time of manufacture.
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Lymphokine-activated killer-cell traffic in
metastatic melanoma
SIR,-Mr Swift and colleagues (June 22, p 1511) report the
successful imaging of colorectal metastases with I I Indium-labelled
tumour-activated killer lymphocytes (TAK). They mention the
advantages of TAK cells over tumour-infiltrating lymphocytes
(TIL)-in that they are not restricted by tumour histology or stage,
are easily handled, and are independent of interleukin-2 support in
vivo.
We have lately reported the imaging of melanoma metastases
with radiolabelled lymphokine-activated killer (LAK) cells in four
of six patients. Additional interleukin-2 infusion was not necessary.’
Metastases have so far been demonstrated by LAK-cell
scintigraphy in 8 (57%) of 14 patients. These cells can be produced
quickly and easily. However, only 1 x l0a to 1 x 109 cells (which
were used in our protocol) can be obtained with ease by
leucapheresis. In contrast to TAK, LAK cells were able to image
lymph-node, bone, skin, and gastrointestinal metastases, but not
parenchymatous metastases.
Two patients gave informed consent for biopsy of
scintigraphically-positive metastases, and we could therefore
analyse the peritumoural infiltrate with a panel of monoclonal
antibodies (APAAP-staining of cryosections). Activated T-helper
(CD3, CD4, CD25) lymphocytes were identified as the main
population in the reactive infiltrate in these 2 patients. No natural
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killer (CD 16, CD56) cells were seen. This observation suggests that
from the heterogeneous cell populations included in LAK-cells,
T -lymphocytes but not natural killer cells can migrate to tumour
sites in melanoma patients. Tumour recognition and traffic are
probably restricted to specific T lymphocytes, as is also suggested
by Swift and colleagues’ data. However, the peripheral blood seems
to contain a considerable number of these T cells, which can be used
for tumour imaging after an interleukin-2-induced short-time
activation.
Out of the 14 patients who received radiolabelled LAK-cells, 5
were treated in a clinical trial with dacarbazine and interleukin-2.3
Of 3 scintigraphically-positive patients, 2 responded to the
treatment, whereas the 2 negative patients did not respond.
Although these preliminary data should be interpreted with
caution, we postulate that metastases respond to immunotherapies
that use interleukin-2 possibly through a T lymphocyte-tumour cell
HLA-DR-dependent interaction.3 LAK-cell scintigraphy might
be a fast and economic method to analyse individual properties and
might have prognostic relevance for immunotherapies that use
interleukin-2.
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Clinical spectrum of mitochondrial DNA
mutation at base pair 8344
SIR,-Dr Hammans and colleagues (June 1, p 1311) identify a
mutation at base pair 8344 of the mitochondrial genome in blood
samples of 5 of 7 patients with the syndrome ofmyoclonic epilepsy
and ragged red fibres (MERRF), confirming previous studies with
muscle mitochondrial DNA.l,2 This mutation, which is in the
mitochondrial gene for lysine transfer RNA (tRNAlys), was also
found in 1 patient with myoclonus and ataxia who lacked ragged red
fibres, but was absent in many other syndromes associated with
mitochondrial disease. We describe further phenotypes associated
with this mutation.
The clinical spectrum of MERRF is broad relative to the other
causes of progressive myoclonus epilepsy from which it should be
distinguished.3 We have reported 13 patients with MERRF,
including one family with 6 affected members.4 The 2 most severely
affected (subjects 5 and 6) had the pathological features of Leigh’s
syndrome, in addition to the system degeneration characteristic of
MERRF.4 We have now identified the tRNAlys mutation in this
family. This confirms Hammans and colleagues’ observation of
Leigh’s syndrome lesions at necropsy in 1 of their MERRF patients
with this mutation. The neuropathological lesions characterising
Leigh’s syndrome are strikingly different from those in
uncomplicated cases of MERRF, yet they now seem to be
consequences of the same mitochondrial DNA mutation in some
families. On the basis of positron emission tomographic data,4 we
have suggested that such clinicopathological diversity can be
explained by the peculiarities of mitochondrial inheritance,
resulting in a spectrum of severity of cerebral metabolic deficits. In
the more severe cases, sudden clinical and metabolic deterioration
can happen with additional stresses, such as fever, resulting in the
pathological picture of Leigh’s syndrome.
The proband of our MERRF family also had large disfiguring
axial lipomas characteristic of multiple symmetric lipomatosis
(MSL) 4s Morphological and biochemical evidence suggests that
familial and sporadic MSL is associated with mitochondrial
dysfunction. An additional patient in our series of MSL, who did
not have myoclonus epilepsy, also had the tRNAlys mutation.
Moreover, the index case of the US family in whom the MERRF
mutation was originally described’ now also has lipomas (J. M.
Shoffner, personal communication). It thus seems that MSL, at
least in some cases, is a manifestation of this mutation.
Although the clinical features of the mitochondrial
encephalopathies are diverse, there are recognisable clinical
patterns, for which genotypic specificity is emerging. The clinician
should now ask for analysis of mitochondrial DNA from blood or
muscle to search for the tRNAlys mutation in cases of possible
MERRF, MSL, or Leigh’s syndrome. However, all three of these
clinical phenotypes are probably also caused by other yet to be
discovered molecular lesions.
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Severity of cystic fibrosis
SIR,-Dr Johansen and colleagues (March 16, p 631) report that
just over three-quarters of patients with cystic fibrosis are
homozygous for the AF508 mutation. The rest have other
mutations, many of which have been recognised, raising the
possibility that the clinical expression of the disease is determined
by the mutation that is present. We report a 45-year-old man in
whom the disease has been unusually mild and whose genotype has
been determined.
The patient was an only child born in 1946. At 5 years old he had
steatorrhoea and respiratory infections, and fibrocystic disease of
the pancreas was diagnosed. He was treated with pancreatic enzyme
supplements and made such good progress that by age 15 the
diagnosis was thought to have been incorrect and the enzyme
supplements were stopped. In his early twenties steatorrhoea
recurred and a jejunal biopsy showed an abnormality consistent
with coeliac disease. Failure of his symptoms to resolve completely
on a gluten-free diet was attributed to non-compliance. At the age of
27 intestinal obstruction developed and at laparotomy the terminal
06 metres of ileum proved to be occluded by inspissated faecal-like
material. At about this time he was investigated for a persistent
productive cough and bronchography showed bilateral
bronchiectasis.
By age 38, when he moved to Devon, he was beginning to be
troubled by breathlessness on exertion. Since then he has had
planned admissions for physiotherapy about twice a year in addition
to postural drainage at home, but he has never required admission
for an acute infective exacerbation. Chest radiography showed
extensive basal emphysema with upper zone fibrosis. His lung
function has declined over the past 7 years (FEV 925 ml and FVC
1929 ml in 1984; and 550 ml and 1350 ml, respectively, in 1991), and
Pseudomwnas aeruginosa has frequently been cultured from his
sputum. His sweat sodium concentration was 124 mmol/1 in 1984.
He has maintained a steady weight during this time (51 kg, height
